Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.
2026 · 3rd Quarter (July 1 - Sep 30)
ANTARES PHARMA, INC.
Filed by BURRELL INTERNATIONAL GROUP LLC.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Oct 1, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- BURRELL INTERNATIONAL GROUP LLC
- Client
- ANTARES PHARMA, INC.
- Filing UUID
- 537ccb24-320b-48fa-b553-9b588f31b625
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.